Profile data is unavailable for this security.
About the company
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immuno therapeutics directly to the lymph nodes (brain center) of the immune system. The Company's lead product candidate, ELI-002, is being developed to treat cancers driven by kirsten rat sarcoma (KRAS). It is conducting a Phase I/II clinical trial of ELI-002 (AMPLIFY-201). Its ELI-007, is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers. Its AMP platform has broad potential applications for the treatment or prevention of cancer, infectious diseases and other diseases.
- Revenue in USD (TTM)0.00
- Net income in USD-38.66m
- Incorporated1998
- Employees32.00
- LocationElicio Therapeutics Inc451 D Street, 5Th FloorBOSTON 02459United StatesUSA
- Phone+1 (857) 209-0050
- Fax+1 (302) 636-5454
- Websitehttps://elicio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kronos Bio Inc | 8.41m | -102.85m | 53.07m | 58.00 | -- | 0.4308 | -- | 6.31 | -1.75 | -1.75 | 0.1425 | 2.04 | 0.0396 | -- | -- | 135,661.30 | -48.41 | -35.47 | -53.26 | -37.14 | -- | -- | -1,222.83 | -7,975.76 | -- | -- | 0.00 | -- | -- | -- | 15.41 | -- | -8.78 | -- |
| Actinium Pharmaceuticals Inc | 81.00k | -42.62m | 53.34m | 49.00 | -- | 1.19 | -- | 658.58 | -1.52 | -1.52 | 0.0029 | 1.43 | 0.0009 | -- | -- | 1,653.06 | -45.12 | -46.98 | -50.13 | -52.71 | -- | -- | -52,620.99 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
| Rapt Therapeutics Inc | 0.00 | -107.49m | 54.80m | 70.00 | -- | 0.5738 | -- | -- | -2.78 | -2.78 | 0.00 | 2.74 | 0.00 | -- | -- | 0.00 | -69.76 | -46.30 | -77.90 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
| Protara Therapeutics Inc | 0.00 | -42.05m | 55.49m | 26.00 | -- | 0.6785 | -- | -- | -2.82 | -2.82 | 0.00 | 3.96 | 0.00 | -- | -- | 0.00 | -46.07 | -37.02 | -50.31 | -38.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 38.71 | -- | -17.67 | -- |
| Connect Biopharma Holdings Ltd (ADR) | 24.12m | -21.25m | 55.53m | 81.00 | -- | 0.5026 | -- | 2.30 | -0.3869 | -0.3869 | 0.436 | 2.00 | 0.1826 | -- | -- | 297,728.40 | -16.09 | -66.24 | -17.73 | -71.36 | -- | -- | -88.10 | -- | -- | -- | 0.0029 | -- | -- | -- | 49.61 | -- | 10.32 | -- |
| Angion Biomedica Corp | 0.00 | -38.66m | 56.03m | 32.00 | -- | -- | -- | -- | -4.83 | -4.83 | 0.00 | -0.161 | 0.00 | -- | -- | 0.00 | -144.89 | -105.91 | -202.49 | -331.69 | -- | -- | -- | -712.81 | -- | -- | -- | -- | -100.00 | -- | 9.31 | -- | -- | -- |
| Maia Biotechnology Inc | 0.00 | -28.08m | 57.14m | 13.00 | -- | 17.94 | -- | -- | -1.62 | -1.62 | 0.00 | 0.1332 | 0.00 | -- | -- | 0.00 | -251.96 | -- | -362.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.91 | -- | -- | -- |
| Shattuck Labs Inc | 4.12m | -85.28m | 58.23m | 75.00 | -- | 0.5264 | -- | 14.12 | -1.85 | -1.85 | 0.0883 | 2.32 | 0.029 | -- | -- | 54,986.67 | -60.08 | -29.14 | -66.66 | -32.42 | -- | -- | -2,067.99 | -565.33 | -- | -- | 0.00 | -- | 154.14 | -40.62 | 14.37 | -- | -19.15 | -- |
| Prelude Therapeutics Inc | 3.00m | -131.52m | 58.34m | 128.00 | -- | 0.2858 | -- | 19.45 | -1.77 | -1.77 | 0.0404 | 3.71 | 0.0132 | -- | -- | 23,437.50 | -57.72 | -47.21 | -63.14 | -51.07 | -- | -- | -4,383.90 | -- | -- | -- | 0.0023 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
| Omega Therapeutics Inc | 6.31m | -78.90m | 59.02m | 93.00 | -- | 2.25 | -- | 9.35 | -1.43 | -1.43 | 0.1145 | 0.4762 | 0.0318 | -- | 6.67 | 67,892.48 | -39.72 | -- | -46.68 | -- | -- | -- | -1,249.54 | -- | -- | -- | 0.3917 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
| Enzo Biochem Inc | 31.91m | -9.82m | 59.56m | 125.00 | -- | 1.06 | -- | 1.87 | -0.194 | -0.5102 | 0.6268 | 1.07 | 0.3073 | 2.34 | 7.25 | 255,256.00 | -9.46 | -14.58 | -13.74 | -19.56 | 45.86 | 40.43 | -30.77 | -26.20 | 2.55 | -- | 0.0047 | -- | 2.72 | -17.03 | 60.77 | -- | -41.75 | -- |
| Prenetics Global Ltd | 22.50m | -45.63m | 59.62m | 320.00 | -- | 0.2757 | -- | 2.65 | -3.79 | -4.14 | 1.86 | 17.70 | 0.0875 | 3.23 | 4.63 | 70,304.00 | -18.52 | -- | -22.89 | -- | 52.31 | -- | -211.67 | -- | 1.98 | -8.67 | 0.0122 | -- | 65.17 | -- | 75.91 | -- | -- | -- |
| enVVeno Medical Corp | 0.00 | -21.24m | 59.62m | 31.00 | -- | 1.26 | -- | -- | -1.33 | -1.33 | 0.00 | 2.70 | 0.00 | -- | -- | 0.00 | -54.12 | -58.43 | -57.23 | -62.76 | -- | -- | -- | -260,799.30 | -- | -- | 0.00 | -- | -- | -- | 4.67 | -- | 21.58 | -- |
| Mural Oncology PLC | 0.00 | -173.30m | 59.97m | 117.00 | -- | 0.2913 | -- | -- | -10.35 | -10.35 | 0.00 | 12.09 | 0.00 | -- | -- | 0.00 | -131.01 | -- | -164.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
Data as of Nov 13 2024. Currency figures normalised to Elicio Therapeutics Inc's reporting currency: US Dollar USD
5.68%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 225.98k | 2.10% |
| Armistice Capital LLCas of 30 Jun 2024 | 100.00k | 0.93% |
| Geode Capital Management LLCas of 30 Jun 2024 | 71.51k | 0.66% |
| Arena Investors LPas of 30 Jun 2024 | 50.00k | 0.46% |
| CM Management LLCas of 30 Jun 2024 | 50.00k | 0.46% |
| Hudson Bay Capital Management LPas of 30 Jun 2024 | 48.72k | 0.45% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 21.90k | 0.20% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 17.41k | 0.16% |
| Meyer Handelman Co. LLCas of 30 Sep 2024 | 13.90k | 0.13% |
| Bridgeway Capital Management LLCas of 30 Jun 2024 | 12.50k | 0.12% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
